BioSpace News Archive

aTyr Pharma, Inc. announced that Leslie A. Nangle, Ph.D., Vice President, Research at aTyr, will present at the International 28th tRNA Conference, which is scheduled to take place June 12 – 16, 2022, at The Ohio State University in Columbus, OH.

Akero Therapeutics, Inc. announced that it will present oral and poster presentations at the Keystone Symposium on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies, being held in Keystone, Colorado, June 12-16.

Aeterna Zentaris Inc. announced its Autoimmunity Modifying Biologicals program has achieved pre-clinical proof-of-concept for the potential treatment of neuromyelitis optica spectrum disorder, a chronic autoimmune disorder of the brain and spinal cord dominated by inflammation of the optic nerve and spinal cord and which can be fatal in approximately 30% of patients within five years of diagnosis.

Inhibikase Therapeutics, Inc. announced that it is advancing its Phase 2a study following review of the study protocol and Phase 1/1b data by the U.S. Food and Drug Administration.

META Pharmaceuticals, China’s first immunometabolism-based small-molecule drug discovery company, announced two consecutive Seed and Pre-A funding rounds totaling 15 million USD.

Neurocrine Biosciences, Inc. announced that it will present new Phase 2 data on the use of crinecerfont in adolescent patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, which demonstrated substantial reductions in adrenal androgens and androgen precursors.

Regulus Therapeutics Inc today announced the dosing of the first healthy volunteer in the Phase 1 SAD study of RGSL8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

IceCure Medical Ltd. announced that its wholly-owned subsidiary, IceCure MedTech Co., Ltd., signed an exclusive distribution agreement for IceSense3 cryoablation systems with Shanghai Medtronic Zhikang Medical Devices Co. Ltd., an affiliate of Medtronic plc and Beijing Turing Medical Technology Co. Ltd.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced Phase 2b results of avexitide in patients with post-bariatric hypoglycemia (PBH) and hyperinsulinemic hypoglycemia (HH) after other gastrointestinal surgeries.

Company receives FDA IND clearance for linsitinib and prepares to initiate Phase 2b clinical trial.